Biotest Aktiengesellschaft (ETR:BIO3)

Market Cap	1.39B
Revenue (ttm)	635.20M
Net Income (ttm)	-24.50M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	23.29
Dividend	0.04 (0.14%)
Ex-Dividend Date	Jul 3, 2025

Volume	2,403
Average Volume	2,562
Open	29.80
Previous Close	29.40
Day's Range	28.40 - 30.60
52-Week Range	24.60 - 31.80
Beta	0.09
RSI	13.60
Earnings Date	Mar 27, 2026

About ETR:BIO3

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomega...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BIO3

Financial Performance

In 2024, ETR:BIO3's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.